Even though the immune system has become familiar with SAR-CoV-2. The emergence of new virus variants remains a hurdle. Professor Dr. Florian Klein, leading a research team at the Institute of Virology in the University Hospital Cologne and the Faculty of Medicine. Has recently released two studies delving into the evolution of the antibody response to SARS-CoV-2. Also, the ingenious strategies employed by the immune system in anticipation of new variants.
The initial paper entitled, “Amplified SARS-CoV-2 Human Immunity After Breakthrough Infection Expands the Existing Memory B Cell Pool.” Has been published in Science Immunology. The subsequent paper title, ” Some Hypermutation Induces Bystander Mutation, Priming SARS-CoV-2 Antibodies for Emerging Variants,” is featured in immunity.
Through a phenomenon called affinity maturation. Antibodies undergo a maturation process over time, characterized by the exchange (mutations) of individual amino acids. This process enhances their ability to detect infectious pathogens effectively. Professor Kleins’s research team has demonstrated that an Omicron infection triggers a renewed immune response in vaccinated individuals. This response is predominantly driven by the reactivation of memory B cells.
Remarkably, the maturation process of antibodies generated by these cells had occurred well in advance of the emergence of Omicron. Indicating that the immune system was pre-equipped. The findings from the two studies underscore the significant impact of the initial encounter with SARS-CoV-2 on the immune system. It suggests the likelihood of its readiness for forthcoming variants as well.
The primary objective was to examine the impact of a third vaccination against the original SARS-CoV-2 strain on the antibody response in healthy individuals. Surprisingly, the third vaccination significantly boosted the overall SARS-CoV-2 immune response. There was minimal additional maturation at the individual antibody level.
READ ALSO: ‘Despacito’ Artist, Retire in the world of Reggaeton Music
Upon analyzing individuals who contracted the Omicron variants BA.1 and BA.2 post-vaccination. A re-evaluation revealed the proliferation of memory B cells capable of producing Omicron-neutralizing antibodies. Intriguingly, these immune cells targeting the Omicron variant were present before any contract with Omicron and were not induced by it.
Furthermore, the study explored the molecular mechanism of affinity maturation. Revealing that some modification during this process is random rather than intentional. Surprisingly, these random modifications proved crucial for neutralizing Omicrons variants.
Researchers successfully utilized these biological insights to modify a therapeutic antibody. Originally ineffective against Omicrons, it effectively neutralized Omicron variants.
In conclusion, the study sheds light on how the human immune system responds to a new virus and it’s evolving variants. The newly discovered broad neutralizing antibodies have therapeutic potential. Offering effective prevention against newer Omicron variants.
